Taken together, these findings show that TF alleviate PM2.5-induced NAFLD via regulation of IRs-1/Akt and CYP2E1/JNK pathways, which may have potential for further development as novel therapeutic agents for NAFLD. The gene discussed is MAPK8; the disease is metabolic dysfunction-associated steatotic liver disease.